76 results about "Infectious arthritis" patented technology

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The invention discloses medicinal liquor for treating rheumatic arthritis and chronic infectious arthritis, which comprises the following raw materials in parts by weight: 33-38 parts of Chinese parsnip root, 8-13 parts of asarum, 28-33 parts of the root of bidentate achyranthes, 28-33 parts of ligusticum sinense oliver, 28-33 parts of notopterygium root, 28-33 parts of radix angelicae pubescentis, 23-28 parts of prepared monkshood, 28-33 parts of cassia twig, 28-33 parts of pawpaw, 28-33 parts of radix clematidis, 28-33 parts of cortex acanthopanacis, 28-33 parts of semen coicis, 28-33 parts of corydalis tuber, 28-33 parts of large-leaved gentian, 4-9 parts of long-noded pit viper, 28-33 parts of the root of fangji, 28-33 parts of rhizoma typhonii, 28-33 parts of ligusticum wallichii, 28-33 parts of zaocys dhumnade, and 7000-8000 parts of 50-60-degree white wine. The medicinal liquor disclosed by the invention has the advantages of being low in cost, high in curative rate and free from toxic and side effects; stimulation of the existing medicines on gastric mucosa is overcome; simultaneously, the medicinal liquor disclosed by the invention also has the functions of tonifying liver and kidney.

Human aggrecanase and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting aggrecanase activity in a host and methods of treating disease conditions associated with aggrecanase activity, e.g. rheumatoid arthritis, osteo-arthritis, infectious arthritis, gouty arthritis, psoriatic arthritis, spondolysis, sports injury, joint trauma, pulmonary disease, fibrosis, and the like.

The invention discloses the structure of four novel bakkenolide compounds extracted from Petasites tricholobus Franch. having a formula (1), the process for extraction and separation, and the use of the compounds in preparing medicament for the treatment and prevention of diseases possibly related to theramine and / or leukotrienes constituents, including asthma, allergic rhinitis, nasal sinusitis, conjunctivitis, food allergy, psoriasis, urticaria, pruritus, eczema, chronic infectious arthritis, enteropathy, nervous disease and otitis.

The invention discloses a paeoniflorin aromatic ester derivative, a preparation method and applications of the paeoniflorin aromatic ester derivative. The general structure formula of the paeoniflorin aromatic ester derivative is as follows: in the formula, R is selected from benzoyl, phenylsulfonyl, phenylacetyl, benzene propionyl, benzene acryloyl, p-chlorobenzoyl, 3, 5-dimethoxybenzoyl, 2-( acetoxyl group) benzoyl, 2-methyl-4-(2'-methyl propyl) phenylacetyl or 2-[(2', 6-dichlorophenyl) amino]- phenylacetyl. The preparation method comprises the steps of taking paeoniflorin as raw materials, conducting esterification on the paeoniflorin in a solvent through aromatic acyl chloride or aromatic anhydride, then conducting washing and column chromatography to obtain the paeoniflorin aromatic ester derivative. The paeoniflorin aromatic ester derivative has the advantages that the bioavailability of the paeoniflorin is improved and the anti-inflammatory action is strong, and can be made into injection, tablets, capsules, dropping pills and particles for treating chronic infectious arthritis.

The invention relates to a Chinese medicinal capsule for treating chronic infectious arthritis and rigid rachitis and process for preparation, wherein the raw materials include agkistrodon acutus, black-tail snake, black ants, ginseng, asaryl, scorpion, earthworm, large-leaf gentian root, seed of nuxvomica, dried rehmannia root, eucommia bark and epimeddium.

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The invention relates to a medicinal oral preparation, i.e., a saussurea involucrata drop pill for treating rheumatic arthritis, chronic infectious arthritis and dysmenorrheal, which has the advantages of high biological availability, quick-speed medicine release, quick-speed effect, less toxic and side effects, higher medicinal content, smaller amount of administration, accurate administration dosage, easy administration, low price, and facilitated carrying. The medicine is prepared through the conventional drop pill preparing process.

The invention discloses an integrin blocker polypeptide as well as a preparation method and application thereof, and belongs to the field of biopharmacy. The integrin blocker polypeptide only has 9 to 17 amino acids from the polypeptide I to the polypeptide X, and is synthesized by using a solid-phase synthesis method, so that the integrin blocker polypeptide also has an in-vivo immune protection function and can be used for treating arthritis even the number of the amino acids in the integrin blocker polypeptide is reduced. The integrin blocker polypeptide has the function of inhibiting neovascularization and has the activity of inhibiting endothelial cell migration so as to prevent and treat diseases relevant to blood vessels and inflammations comprising oculopathy relevant to neovascularization. The integrin blocker polypeptide has the high anti-tumor activity to various types of tumors, so that the cost is greatly lowered. The integrin blocker polypeptide has the good function for treating chronic infectious arthritis, so that the adaptability and the applicable diseases of the integrin blocker polypeptide are increased. Thus, the social and economic values of the integrin blocker polypeptide are enlarged.

An alkannin derivative as immuno-suppressive agent and its metallic complex compound with a chemical constitution formulas III and IV disclosed in the specification, wherein in formula III, R is C1-6 saturated, unsaturated and aromatic acyl, in formula IV, R is hydrogen, C1-6 saturated, unsaturated and aromatic acyl, M is metallic Cu, Ca, Zn. The present invention realizes immunological suppression effect, thus can be used for treating diseases relating to human body autoimmune including chronic infectious arthritis, scleredema, lupus erythematosus, HIV infection and malignant tumor.

The invention discloses the use of spicebush root alkaloid in preparing medicament for treating chronic infectious arthritis and other immune diseases. Animal tests show that, the spicebush root alkaloid can substantially alleviate the degree of mouse joint pathological changes, and lower the mouse feet tumefaction degree caused by arthralgia due to wind-cold-dampness.

The invention relates to a traditional Chinese medicine preparation for treating rheumatism and internal lesion caused by overexertion, which is prepared from 45 active pharmaceutical ingredients, including angelica, red paeonia, roasted frankincense, roasted myrrh, safflower and the like. The preparation can be capsules, tablets, pills, powder or medicinal wine. The preparation method comprises the following steps: extracting the active pharmaceutical ingredients with water, preparing thick paste, drying, pulverizing to obtain water extraction medicinal powder, and preparing the water extraction medicinal powder into various preparation formulations; or pulverizing the active pharmaceutical ingredients to obtain raw medicinal powder, and preparing the raw medicinal powder into various preparation formulations; or putting the active pharmaceutical ingredients into a container, adding grain wine, soaking, filtering, and removing medicinal dregs to obtain the medicinal wine. The active pharmaceutical ingredients are organically combined according to the principle of 'monarch, minister, assistant and guide' to have synergistic action, so that the traditional Chinese medicine preparation has favorable curative effect on rheumatism and internal lesion caused by overexertion, and can treat both the symptoms and root causes. The traditional Chinese medicine preparation has obvious curative effect for treating limb arthralgia, rheumatoid arthritis, chronic infectious arthritis, gouty arthritis, lumbar vertebral disc pathological changes, scapulohumeral periarthritis, cervical pathological changes and the like. The traditional Chinese medicine preparation is prepared from pure traditional Chinese medicines, is convenient to use, has high safety and reliability, has no toxic or side effect on the liver, kidney, lung, stomach and spleen, and can be used for a long time.

The invention relates to the application of ginkgolic acid in treating arthritis. The ginkgolic acid comprises ginkgoic acid, ginkgol, ginkgoic diphenol and the like and can be obtained from the extracts of the parts of the leaves, the fruits, the episperms, the rhizomes and the like of gingkoes by a chemical separation method. The arthritis is rheumatoid arthritis, chronic infectious arthritis, gouty arthritis, osteoarthritis and the like. A medicine, a medical appliance or a disinfector preparation which contains the ginkgolic acid and is used for treating the arthritis contains 0.001 to 80 percent of ginkgolic acid (calculated according to weight percent) and an external preparation substrate or an acceptable carrier which is generally used pharmaceutically; and the preparation is any external preparation formulation which is given pharmaceutically. The research of a pharmacological experiment shows that the ginkgolic acid has the favorable actions of improving arthrocele, relieving joint injury and suppressing local inflammation to an animal model with the arthritis. Clinical trial shows that the ginkgolic acid has an obvious therapeutic action to each type of arthritis, and the effective rate reaches more than 90 percent. In use, the ginkgolic acid is safe and has no side effect.

The present invention provides type II collagen from cyanea arctica and the preparation process, pertaining to the natural biological active material and the technical art of preparation. The present invention provides novel natural halobios type II collagen. Being operated according to the present invention, 0.5 percent wt. type II collagen with purity up to more than 85 percents can be obtained. The type II collagen is originally white powder with fishy smell, which contains 85 to 99 percents wt. protein and almost no sugar. The type II collagen is nontoxic and has the reactivity of II collagen such as oral medication, inducement, immunological tolerance, prevention and treatment of chronic infectious arthritis.

The invention relates to a formula for treating and preventing arthritis, synovitis and other orthopaedic diseases and complicating diseases and discloses a main compound extracted from mangosteen:Garcinia mangostana. In the main compound, alpha-mangostin serving as a main ingredient is used in combination with various common filters in pharmaceuticals industry to prepare various proper formulations including tablets, capsules, powders, suppositories and the like for oral or external use for treating and preventing arthritis diseases such as rheumatoid arthritis, chronic infectious arthritis, post-traumatic arthritis, osteoarthritis and purulent arthritis as well as complicating diseases of the arthritis diseases such as inflammations of finger joints, metacarpophalangeal joints, wrist joints, elbow joints, shoulder joints, knee joints, spondyl joints, ankle joints, metatarsophalangeal joints and other joints. The alpha-mangostin content of the product of the invention is between 0.1 and 99.9 percent. The product manufactured by the formula can relieve the various inflammations and has certain analgesic effect. The product can be used alone or in combination with other substances.

The invention discloses a pathogenic wind dispelling powder for treating arthritis, which comprises Sichuan aconite root, Kusnezoff monkshood root, jack-in-the-pulpit tuber, spiderherb seed, tortoise shell, hairy birthwort, camphor, boneol, pubescent angelica root, frankincense, myrrh, seed of nuxvomica, Chinese dittany bark, joints, musk, gastrodia tuber, and scorpion. The powder is mainly used for treating rheumatism and chronic infectious arthritis.

The invention relates to a monoclonal antibody capable of neutralizing CYR61 and applications thereof and a hybrid tumor capable of generating the monoclonal antibody. The technical scheme adopted by the invention relates to the monoclonal antibody secreted by the mouse anti-human CYR61 monoclonal antibody hybrid tumor CGMCC No.2766 or CGMCC No.2767, and the applications of the monoclonal antibody to preparation of a medicament for treating rheumatic disease, wherein the rheumatic disease is the chronic infectious arthritis. The invention has the advantages that: (1) the self-prepared monoclonal antibody can research pathogenesis of CYR61 in rheumatoid arthritis and can accurately position the expression of CYR61 and detect the CYR61 level of the blood serum and the lesion sites (such as joints); (2) the monoclonal antibody can be used for preparing a detection kit so as to distinguish clinical diagnostics of osteoarthritis and rheumatoid arthritis; and (3) the monoclonal antibody also can search the combination epitope where the CYR61 on the surface of the synovium and in the synovial of the rheumatoid arthritis patient can be neutralized, and provides the screening basis for preparing a humanized antibody which can neutralize the CYR61 in the next step.

The invention relates to medicinal liquor for treating rheumatic arthritis. The medicinal liquor for treating rheumatic arthritis is prepared from 30 grams of safflower, 30 grams of Chinese angelica, 50 grams of long-noded pit viper, 30 grams of scorpion, 25 grams of frankincense, 40 grams of ground beeltle, 40 grams of eucommia bark, 40 grams of ningpo yam rhizome, 40 grams of divaricate saposhnikovia root, 40 grams of clematis root and 40 grams of mulberry twig. The accuracy of weight of the medicaments is + / -10 percent. The medicinal liquor for treating rheumatic arthritis is mainly used for treating rheumatic arthritis, also has good treatment effect on osteoarthritis and chronic infectious arthritis, avoids toxic and side effects, and is remarkable in treatment effect and high in cure rate.

The invention discloses a traditional Chinese medicine for treating chronic infectious arthritis, belonging to the technical field of treatment of orthopedics and traumatology. The traditional Chinese medicine is characterized by being prepared from the Chinese medical herbs in parts by weight: 15-20 parts of Chinese angelica, 15-20 parts of rhizoma rehmannia, 10-15 parts of cocklebur fruit, 20-25 parts of garter snake, 10-15 parts of eupolyphaga, 3-5 parts of scorpio, 10-15 parts of roasted squamamanitis into puffy with sand, 30-35 parts of rhizoma dioscoreae nipponicae, 20-25 parts of epimedium, 25-30 parts of caulis spatholobi, 15-20 parts of cortex erythrinae, 5-8 parts of dung beetle, 2-4 parts of centipede and 15-20 parts of medicinal cyathula root. According to the pathological mechanism principle of the chronic infectious arthritis and the reason causing the chronic infectious arthritis, a pure Chinese medicine formula is adopted, an oral liquid, or powder, or a tablet, or a capsule is prepared through extracting effective components; and an externally applied agent plaster can also be prepared. After the traditional Chinese medicine is orally taken, the chronic infectious arthritis can be effectively treated, and an ideal effect is achieved.

The invention discloses application of an affine cudweed extractive in preparing medicaments for preventing and curing chronic infectious arthritis. By experiments, the affine cudweed extractive has the applications that (1) an in-vitro anticomplement activation classic approach cell hemolysis test confirms that the affine cudweed extractive has a stronger anticomplement activity and can be used for autoimmunity inflammation diseases caused by abnormal anticomplement activation; (2) in a model experiment that foot sole acute inflammation of a mouse is caused by carrageenin, a result shows that the affine cudweed extractive has an obvious action on inhibiting the foot tumescence of the mouse; and (3) in an experiment that the affine cudweed extractive has the action on preventing and curing II type collagen chronic infectious arthritis of a rat, a result indicates that the affine cudweed extractive has an extremely obvious action on inhibiting the foot sole tumescence of a rat model with chronic infectious arthritis induced by II type collagen. Therefore, the invention provides a new approach for clinically curing the chronic infectious arthritis, and the preparation method of the affine cudweed extractive is simple and convenient and has a larger actual application value.

The invention discloses a traditional Chinese medicinal preparation for treating rheumatic arthritis and chronic infectious arthritis, which is prepared from the following traditional Chinese medicines in part by weight: 50 to 80 parts of rhizoma heterosmilacis japonicae and 30 to 60 parts of raw rehmannia root. The traditional Chinese medicinal preparation may be formed into particles, capsules and tablets; and a dose of 13g is taken each time. When the traditional Chinese medicinal preparation is used for treating rheumatic arthritis and chronic infectious arthritis, an obvious effect is produced after administration, joint pain is relieved, join swelling is eliminated, the joint function is restored and improved, the effectiveness is over 98 percent, and the curing rate is over 78 percent. The formula has only two traditional Chinese medicines, so the preparation is simple and the price is low.

The invention discloses a traditional Chinese medicine preparation for treating rheumatic arthritis, which is prepared and verified repeatedly through clinical tests, and complies with a theory of traditional Chinese medicines. The traditional Chinese medicine preparation is characterized in that bauhinia roots, nothapodytes pittosporoides, delavay schefflera roots, desmodium racemosum thunb, piper hancei, radix araliae armatae, avicennia pricklyash roots and sassafras are taken as monarch drugs for expelling wind-damp, relaxing muscles and tendons, promoting blood circulation to stop pain, and strengthening bone and musculature; grossedentate clematis roots, slender-spike gouania stems and leaves, Japanese spicebush bark, serrate glorybower herb, manynerve embelia fruits, hooked spikemoss and goshawk bones are taken as ministerial drugs for strengthening the efficacies of expelling wind, removing cold and relieving rheumatic arthralgia; achnatherum inebrians, phlomis umbrosa, aphananthe aspera, protruding eucalyptus leaves, loosestrife and amur grape stems are taken as adjuvant drugs for tonifying a kidney, benefiting essential qi, enriching blood, calming mind, clearing away heat, drying dampness and warming channels to relieve pain; and oriental grape roots, hemiphragma heterophyllum, nandina roots, oriental bitteraweet leaves, common exbucklandia stems, marsh equisetum and arachnoid cyanotis roots are taken as conductant drug for warming and activating meridian, expelling wind, removing cold and guiding the drugs to illness location. The traditional Chinese medicine preparation for treating rheumatic arthritis, chronic infectious arthritis and arthralgia, has unique curative effect, and removes pain of a patient fundamentally.

The invention relates to a combination for treating bone disease, which is prepared by raw materials of teasel root, drynaria rhizome, lumbricus, red flower, cistanche and rehmannia and can be used for simultaneously treating various bone diseases including rheumatic arthritis, chronic infectious arthritis, degenerative joint disease, ankylosing spondylitis, cervical spondylosis, lumbar spondylosis, scapulohumeral periarthritis, osteoproliferation, femoral head necrosis and the like. According to a large amount of clinical application, numerous patients are thoroughly cured in a short time, and the curative rate is as high as above 90.8%.

The invention relates to the field of medicines, particularly to polypeptide which restrains the nuclear factor-KB, and can be used for preventing and treating chronic infectious arthritis. The sequence is KRSGGGFPAAV and is a bran-new sequence. The invention has the benefits that the nuclear factor-KB polypeptide inhibitor is capable of treating the chronic infectious arthritis and has potential value in development of new medicaments.

The invention relates to a traditional Chinese medicine for treating chronic infectious arthritis, and belongs to the field of traditional Chinese medicines for treating rheumatism. The traditional Chinese medicine aims to have good effect and quick response. The traditional Chinese medicine is prepared from raw materials such as gentiana macrophylla, Chinese angelica, radix stephaniae tetrandrae, kadsura pepper stem, rehmanniae praeparatum, glossy ganoderma, earthworm, notoginseng root, ovientvine and the like. The traditional Chinese medicine has the effects of strengthening body resistance and archaeus, supplementing qi and nourishing blood, promoting blood circulation by removing blood stasis, promoting channels and collaterals and dispelling the wind and arthritis, and has the advantages of obvious effect, definite medicinal effect and quick response.